Evonetix, a next generation synthetic biology company leveraging semiconductor technology to generate long, double-stranded DNA with high-fidelity at scale, has added Colin McCracken as CEO. To date, the UK-based platform company has raised $45M led by Foresite, DCVC, Draper Esprit and Morningside.
McCracken brings over twenty years’ experience in commercial and business development roles. Prior to joining Evonetix he was SVP & Chief Commercial Officer at Fluidigm where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President & General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President & Head of European Sales at Life Technologies and National Sales Manager at Qiagen. See Full Press Release HERE
On the heels of a robust Series A raise co-led by F-Prime Capital and OrbiMed, CHARM Therapeutics has added veteran biotech entrepreneur Gary Glick as Chairman. CHARM intends to utilize 3D deep learning in small molecule drug discovery with an initial emphasis on cancer.
Gary Glick, President and CEO of Odyssey Therapeutics, is a formidable chemist and serial biotech entrepreneur. He has founded several successful companies, including Scorpion and IFM Therapeutics. While CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol-Myers Squibb in a transaction valued more than $2.3B. Prior to Odyssey, in 2020, he co-founded and launched Scorpion Therapeutics. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270M across two financings.
Glick is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive. Gary received his Ph.D. in Organic Chemistry from Columbia University and completed an NIH postdoctoral fellowship in Organic Chemistry at Harvard University.
On the heels of an $82M series C fundraise, Vestaron, a leader in peptide-based biological crop protection, backed by Cavallo Ventures, Novo Holdings, Northpond Ventures, and more, has expanded its leadership team with the appointment of Juan Estupiñan as CFO. Juan will have global responsibility for corporate finance, FP&A, corporate tax, investor relations, and corporate communications.
In his prior role, Juan served as Vice President, Finance and Accounting, and Controller at neurotherapeutics biotech Aptinyx, playing a key role in the series A and B private financing rounds, the Initial Public Offering, and two subsequent funding rounds. Juan received his Bachelor of Science in Accounting and Finance from Indiana University and Master of Business Administration from Northwestern University, Kellogg School of Management.
Recursion Pharmaceuticals (RXRX), a clinical-stage biotechnology company industrializing drug discovery by decoding biology has added Ryan Kelly as Chief Communications Officer where he will be responsible for external and internal communications. Mr. Kelly previously served as Vice President, Global Marketing and Communications at Virgin Hyperloop where he supported commercializing the company’s technology through global strategic communication campaigns. SEE FULL PRESS RELEASE HERE
Tenpoint Therapeutics, a clinical-stage cell therapy targeting unmet needs in ocular diseases, has added Kali Stasi, M.D., Ph.D., as its Senior Vice President of Clinical Development.
Previously, Kali served as a Translational Medicine Director at the Novartis Institutes for Biomedical Research, where she served as a clinical development leader for cell & gene therapy products programs pertaining to front- and back-of-the-eye indications. Prior to Novartis, Kali served as a professor & researcher at the University of Pennsylvania.
Kali Stasi earned her M.D. and Ph.D from the University of Patras, in Greece. She completed residencies at The Massachusetts Eye & Ear Infirmary, Mount Sinai Hospital, Johns Hopkins Hospital, and the Albert Einstein College of Medicine.
"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."Find out more Read the Case Study
"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."Find out more
"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."Find out more
"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."Find out more
“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”Find out more
Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.
Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.
The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.
Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.
Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.
Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.View all news